Advisory Board October 30, 2025

Eli Lilly and NVIDIA have partnered to build the most powerful supercomputer owned and operated by a pharmaceutical company,” which will be used to power an “AI factory” for drug discovery and development.

Eli Lilly, NVIDIA announce new AI partnership

Earlier this week, Eli Lilly announced that it was partnering with NVIDIA to build “the most powerful supercomputer owned and operated by a pharmaceutical company.” The supercomputer will be the first NVIDIA DGX SuperPOD with DGX B300 systems and will run on a single network powered by over 1,000 graphics processing units.

According to Lilly, the new supercomputer will be used to power an “AI factory,” which will take in data, train models based on internal company experiments, and...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: AI (Artificial Intelligence), Biotechnology, Partnerships, Pharma, Pharma / Biotech, Technology, Trends
Related Articles:
283: A candid conversation: Physicians on the front lines of GLP‑1 care
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
Q&A: New PQA Resource Highlights 40 Projects Targeting Social Determinants of Health
NVIDIA and Lilly Announce Co-Innovation AI Lab to Accelerate Drug Discovery
Data Visualization is Broken in Biotech: Q&A with Sunitha Venkat

Share Article